Dogs given 920 cGy of total body irradiation (TBI) followed by autologous marrow infusion uniformly achieve sustained hematopoietic reconstitution. We have previously shown that administration of the anti-MHC class II monoclonal antibody ( 
In dogs, MHC class I1 antigens are typically expressed very widely, including not only monocytes, dendritic cells, B lymphocytes, and activated T lymphocytes, but also resting T lymphocytes." Canine CFU-GM and CFU-GEMM express both DLA-DR and -DP homologue^.'^ We have shown in previous studies in canine models that MHC class 11-expressing cells play a central role in hematopoiesis. In vitro treatment of canine marrow with the murine anti-MHC class I1 monoclonal antibody (MoAb) 7.2 and rabbit complement before transplantation prevents autologous reconstitution after 920 cGy of total body irradiation (TJ31).'s Conversely, positively selected (7.2 positive) marrow cells are capable of sustained hematopoietic reconstitution in lethally irradiated dogs. 17 Fitchen et aI2 have shown that cytolytic treatment of murine hematopoietic precursor cells with anti-I-E (homologous to HLA-DR), but not with anti-I-A (homologous to HLA-DQ) antibodies prevents the formation of CFU-S in vivo.' These data are of interest in view of the more recent findings that a pluripotent DR+ hematopoietic precursor cell originates from a DR-fetal stem cell that also gives rise to DR-stromal cells. ' The presence of class I1 molecules on stem cells could have significant clinical implications because of HLA-restricted cell collaboration in hematopoiesis,''s20 a phenomenon potentially relevant to the interactions between transplantable cells and yet to be characterized accessory cells in the hematopoietic microenvironment." In recent studies we showed that in vivo administration of anti-MHC class I1 MoAb H81.98.21 to dogs immediately after TB1 and infusion of unmanipulated autologous marrow resulted in delayed graft failure." The same MoAb interfered with the function of high proliferative potential-long-term culture initiating cells of human marrow in vitro. 23 In the present study we show that a second anti-MHC class I1 MoAb, BlF6, recognizing a different epitope?' has the same effect on hematopoiesis as does H81.98.21 if dosed appropriately. Furthermore, we show that graft failure involves all lineages and can be consistently abrogated by the administration of recombinant canine stem cell factor (SCF), a c-kit ligand."zZ5 Cells. PBL and marrow mononuclear cells were obtained by separation of heparinized blood or marrow over a Ficoll-Hypaque gradient."
Bone marrow (BM) core biopsies were obtained with a 2-mm bore needle from the humerus of ketamine anesthetized dogs. One half of the BM cores was immediately placed in ice-cold saline and snap-frozen for immunophenotyping. The other half was fixed and processed for pathologic and histologic examination by standard techniques.
Determination of free MoAb in PB and BM plasma. Plasma samples from PB and BM were obtained sequentially via venipuncture or BM aspirates, and separated in a refrigerated centrifuge. Plasma was pipetted off and frozen at -20°C until use. PBL from normal dogs were incubated with PB plasma or BM plasma at various dilutions in parallel with purified MoAb, washed, labeled with FITC-conjugated goat-antimouse antibody F(ab')2 (Caltac, South San Francisco, CA), and prepared for cytofluorometric analysis as described.l6
Immunophenoryping of BM sections. Snap-frozen BM biopsies were sectioned on a cryostat and fixed on slides as described. 34 They were then incubated either with FITC-conjugated, secondary antibody only [goat-antimouse F(ab')z], or with primary antibody as appropriate, followed by secondary antibody.
Iodination of MoAbs. MoAbs were labeled with '"I-Na using the iodogen method as d e~c r i b e d .~~"~ The immunoreactivity (proportion of antibody molecules in a preparation which was capable of binding to antigen) was 60% to 96%%; avidity of radiolabeled antibodies was determined as previously d e~r i b e d ?~ Determination of cell binding sites. Cell binding sites were determined by standard t e c h n i q~e s .~~-~~ Briefly, stepwise dilutions of '%I-labeled MoAb were bound to fixed numbers of cells, the suspensions centrifuged, and bound and free radioactivity (CPM) quantitated by gamma counting. The ratio of bound/free CPM (vertical axis) was plotted against the concentration of MoAb, and the X intercept was taken as a measure for antigen binding sites per cell. Data were corrected for the immunoreactivity of the MoAb and for nonspecific binding?7
Endocytosis assay. Marrow cells and PBL were washed in icecold serum-free RPMI 1640 and pelleted by centrifugation. Ice-cold iodinated antibody was added to the cell pellet at a ratio of 40 ng of MoAb per lo6 cells in a volume of 0.5 mL. Cells were incubated with iodinated antibody on ice for 1 hour, washed twice with 10 mL of ice-cold RPMI, and maintained on ice. At various time intervals, cell cultures were assayed for supernatant radioactivity, surface membrane-bound radioactivity, and intracellular radioactivity as described elsewhere." Briefly, at 0,0.25,0.5, l, 2,4,10, and 24 hours, cells were pelleted at 4°C at 300g for 3 minutes. Supernatants were transferred into fresh tubes for gamma counting (Packard COBRA, Laguna Hills, CA). Surface-bound MoAb was stripped from the cell membrane by two consecutive 15-minute acid (pH 2) washes. The two acid washes were pooled, and "acid releasable" '"I-MoAb was determined by gamma counting. Cells were maintained at 4°C. Nonspecific binding to cells lacking the target antigen was consistently less than 1% of specific binding. After stripping of surface antibody, cell pellets were harvested and assayed for internalization MoAb degradation was performed as described.39P0 Briefly, cell supernatants were mixed with an equal volume of tetrachloroacetic acid (TCA) to precipitate protein-bound '251-MoAb. These precipitates were washed again in TCA, and pellets and non-TCA-precipitable washes were gamma counted separately.
Long-term EM culrures. Long-term canine marrow cultures were established as described by Schuening et al. 41 Triplicate cultures were maintained at 37°C in a water saturated 5% COz/air atmosphere. Cells were not treated with hemolytic buffer. After 8 to 10 days, nonadherent cells were removed, the adherent layer was maintained, and the cultures were then recharged with fresh marrow from the same dog. MoAb was added at concentrations determined in ancillary experiments. At weekly intervals, nonadherent cells were harvested, centrifuged, and counted, and aliquots assayed for CFU-GM. The remaining cells were returned to the long-term culture flasks with old medium and fresh medium mixed 1:l. CFU-GM, assayed in quadruplicate, were counted at 14 days."' EM tramplantation. TBI, marrow infusion, and posttransplant care have been described.z2sz6 Briefly, marrow was obtained by needle aspirations from femora and humeri of anesthetized dogs and stored at 4°C. Irradiation consisted of a single dose of 920 cGy TB1 delivered at 7 cGy/min from two opposing "CO sources. This dose is more than twice the LDw for dogs. Autologous marrow, 0.6 to 4.4 X 10' cellskg body weight was infused intravenously (IV) immediately after TBI.
Administration ofMoAb and SCF. Three dogs were given MoAb B1F6 at a dose of 1.2 mgkgjd IV, and three at a dose of 0.6 mg/ kg/d on days 0 through 4 (one of these dogs was included in a previous report)." Four dogs were given MoAb H81.98.21 at a-dose of 0.6 mgkg/d IV on days 0 through 4 (three of these dogs were included in a previous report)." Eight dogs were given MoAb H81.98.21 at 0.6 mgkgjd and, in addition, received recombinant canine SCF, 200 pgkgjd subcutaneously, either on days 0 through 6 (n = 3) or on days 0 through 20 (n = 5). Among the five dogs who were to receive SCF until day 20, two died before completing the course on days 11 and 15, respectively. Both deaths were related to anesthesia administered before obtaining marrow biopsies, and these two dogs were not further considered in the analysis. One dog was given SCF only (days 0 through 6) and no MoAb. MoAb H81.98.21 lH81.9) at 10 pg/mL l-0 -1 compkdy prevented the growth of CFU-GM, whereas eventual recovery was wen with MoAb B1F6 at the same dose l-A -1. However, MoAb B1F6 at 100 pg/mL l-A -1 inhibited CFU-GM to the same extent es H81.98.21 at the lower dose. MoAbs 6.4 Iantimouse Thy 1.1) or G M 6 lantlhuman Ilb/llla) a t concentrations of 1 to 100 pg/mL had no effect Icontroll. Shown are the moans of triplicate long-term cultures each assayed for CFU-GM in quadruplicate.
For
RESULTS
Based on previously published data:* our working hypothesis was that differences in the in vivo effects of MoAbs H81.98.21 and B1F6 were epitope dependent. Therefore, we attempted to determine functional differences between these two MoAbs in vitro.
Estimation Endocytosis results are summarized in Fig 1. The surfacebound (releasable) fraction of H81.98.21 declined rapidly, resulting in a corresponding increase in free antibody; there was only a short early peak of internalization of antibody.
With antibody BlF6, a gradual decline in releasable antibody with a correspondingly more gradual rise in free antibody was observed, a finding consistent with the slightly higher avidity of this MoAb. Only little MoAb was present in the internalized fraction, and no distinct peak over time was observed. Thus, no significant differences were seen favoring MoAb H81.98.21; in fact, the data suggested an equal or higher potency of MoAb BlF6.
MoAb concentration in PB and BM plasma. Next, we determined whether antibody concentrations reached in vivo or compartmentalization differed between the two MoAbs. Sequential serum and plasma samples were assayed for free MoAb as measured by their ability to label normal PBL. Results with marrow plasma are illustrated in Fig 2. Whereas plasma from an H81.98.21-treated dog (0.6 mgkg) saturated MHC class I1 binding sites on PBL from untreated dogs, plasma from a BlF6-treated dog (0.6 mgkg) failed to do so. Results with PB plasma were identical (data not shown), arguing against differences in compartmentalization and suggesting that clearance of B1F6 was considerably faster than of H81.98.21. Alternatively, B1F6 might bind more extensively to tissues other than the lymphohematopoietic system. In either case, higher doses of B1F6 would be expected to have effects similar to those observed with H81.98.21 at lower doses. We tested this possibility first in long-term marrow cultures.
Long-term BM cultures. MoAb was added to cultures at the time of recharging the flasks with fresh marrow and a second time 1 week later when cells were obtained for the first CFU-GM assays. Results are summarized in Fig 3. At 10 pg/mL, MoAb H81.98.21 completely inhibited the production of CFU-GM and, in addition, resulted in a gradual regression of the adherent layer. The same concentration of B1F6 did not morphologically affect the adherent layer, and inhibited CFU-GM production only transiently. However, as the B1F6 concentration was increased, CFU-GM production decreased progressively, and long-term cultures failed as seen with H81.98.21. MoAbs 6.4 or G3G6 at concentrations of 1 to 100 pg/mL did not affect CFU-GMs, the numbers being identical to those seen in cultures without MoAb.
Effect of BlF6 on in vivo hematopoietic reconstitution after autologous marrow transplantation. Results are illustrated in Fig 4. When MoAb B1F6 was given at 1.2 m a g / d (n = 3), the pattern of initial granulocyte recovery and subsequent graft failure was identical to that observed with H81.98.21 at 0.6 mgkg/d (n = 4) and strikingly different from that seen in three dogs given B1F6 at 0.6 mgkgld, which allowed for normal recovery" (Fig 4, A and B) . Dogs treated with H81.98.21 at 0.6 mgkg or B1F6 at 1.2 mgkg both showed severe marrow aplasia (Fig 4C) . As shown in Fig 4D, this course was correlated with the concentration of free MoAb in marrow plasma: Whereas virtually no free antibody capable of binding to normal canine PBL was present in the plasma of dogs treated with B1F6 at 0.6 mgkg (see Fig 2) , plasma of dogs treated with 1.2 mgkg contained sufficient free antibody to saturate normal PBL.
With intensive posttransplant supportive care, one of three dogs given B1F6 at 1.2 m@g and one of four dogs given H81.98.21 at 0.6 m a g eventually showed granulocyte recovery indicative of survival of some stem cells capable of differentiation. Granulocyte recovery allowed for prolonged survival of these dogs and showed that MoAb treatment had also affected platelets and erythroid lineage as indicated by thrombocytopenia, reticulocytopenia, and anemia. The latter was partially masked by repeated transfusions given to maintain a satisfactory hematocrit and oxygen saturation. The single H81.98.21-treated dog (D193) that had recovered from granulocytopenia, died from severe anemia (hematocrit
Response of MoAb-induced graft failure to SCF. In vitro studies with human marrow suggest that anti-MHC class I1
MoAb interferes predominantly with SCF-dependent prolifera t i~n . *~ If this also applied to dogs in vivo, it might be possible to abrogate graft failure by providing excess exogenous SCF. Thus, dogs were given TBI, autologous marrow, MoAb H81.98.21 (days 0 through 4), and SCF on days 0 through 6 or 0 through 20. Results are summarized in Fig 5. SCF given on days 0 through 6 resulted in a broad early granulocyte peak followed by prolonged neutropenia (but not agranulocytosis) and recovery to normal by day 50; platelets reached normal values by day 60. SCF given on days 0 through 20 was associated with a narrow early granulocyte peak, followed by a brief decline and rapid recovery to normal by day 30; platelet counts became normal by day 40. The dog given SCF and no MoAb posttransplant showed rapid and sustained hematopoietic reconstitution (not shown).
5%).

DISCUSSION
We have shown in the present study that the effect of anti-MHC class I1 MoAbs on hematopoiesis is not epitope dependent, but rather is caused by a more generally applicable class I1 antigen-mediated mechanism. The present results also illustrate that marrow graft failure was not restricted to the myeloid lineage, but affected megakaryocytic and erythroid lineages as well. The administration of recombinant canine SCF posttransplant consistently abrogated MoAb-induced graft failure. It is currently not known whether recov- formation of confluent adherent layers in a human in vitro model. Thus, it is conceivable that a class 11-positive subpopulation of stromal cells, though small, plays a pivotal role in sustaining functional adherent layers. In support of such a mechanism are prelmmry data suggesting that anti"HC class II MoAbs disrupt normal expression of hematopoietic growth factors in stromal cells at the mRNA level." A lack of growth factors could result in a cessation of hematopoiesis, eg, caused by apoptotic cell death as described in other models of in vitro hematopoiesi s! ' O f interest was the observation that an occasional dog treated with either one of the two MoAbs, if maintained on intensive supported care, eventually showed at least pamal hematopoietic recovery. Similarly, in long-tern marrow cultures, there was a slight recovery of CFU-GM production after discontinuation of B1F6 addition. These data suggest that some hematopoietic stem cells survived and received the signals necessary for replication and differentiation.
Greinix et aIz3 showed that MoAb H81.98.21 in a human in vitro model inhibits SCF-dependent growth of high proliferative potential colony-forming cells, also suggesting that interference with growth factor, especially SCF function is an essential feature of the MoAb effect. With this background it appeared appropriate to determine whether in vivo administration of SCF, by providing excess amounts, might overcome MoAb-induced graft failure. This was indeed the case. The kinetics of granulocyte recovery after a l-week course of SCF suggest a positive, albeit transient, effect on final differentiation followed by a slow but eventually sustained granulocyte recovery from a limited stem cell pool. A .?-week course of SCF was accompanied by an initial short and transient rise of granulocytes; this was rapidly followed by sustained recovery, suggesting a faster restoration of the stem cell pool with extended administration of SCF. Platelet reconstitution was also faster with prolonged SCF administration, but still remained slow, possibly because additional factors not replaced (or induced) by exogenous SCF were also inhibited by MoAb treatment. These results are conceptually in agreement with a report by Neta et alJh who showed that the administration of a rabbit polyclonal antibody (P2) against SCF increased the LD50,30 (50% lethality at 30 days after irradiation) in CD2F1 mice from 50% to 100%. In Log Fluorescence Intensity addition, the median survival time was shortened and the number of recoverable marrow cells was reduced in P2-treated mice."' These and additional data on radioprotection led the authors to conclude that SCF is required for emergency hematopoiesis.
Emergency hematopoiesis is also required in the canine model of anti-MHC class I1 MoAb-induced graft failure where only small numbers of stem cells are available. We postulate that the production of SCF is downregulated by MHC class I1 mediated signals." The exact mechanism remains to be determined. The studies described here were performed with complete MoAb. It is conceivable, albeit unlikely, based on ancillary studies reported previously." that Fc receptor binding and antigen cross-linking are involved. Currently ongoing studies using F(ab')? fragments of MoAb will directly answer this question. Preliminary results from cellular and molecular experiments indicate that both complete MoAb and F(ab'), fragments affect in vitro hematopoiesis, and transmembrane signaling. It appears that this results in dysregulation of hematopoietic growth factors and disruption of normal differentiation and maturation, possibly mediated by microenvironmental or accessory cells.
In summary, the present experiments show that MHC class 
